Sandoz accuses Amgen of Enbrel drug monopolization in US complaint
Sandoz has filed a US antitrust complaint accusing Amgen and subsidiary Immunex of unlawfully extending and entrenching a monopoly over the blockbuster drug Enbrel by blocking biosimilar competitors through patent litigation.Sandoz...To view the full article, register now.
Already a subscriber? Click here to view full article